Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.
Related Posts
Emerging Phase II Data Show Evorpacept Improved Tumor Response in Patients with Gastric Cancer
Image Credit: © PIC4U – stock.adobe.com Evorpacept, a CD47 blocker, has returned positive data from the Phase II ASPEN-06 clinical…
Phase III Trial Shows Tezspire Significantly Reduces Nasal Polyps, Congestion in Chronic Rhinosinusitis Patients
Credit: hapsuwanArt | stock.adobe.com Topline results from the Phase III WAYPOINT trial (NCT04851964) show that Tezspire (tezepelumab-ekko; Amgen and AstraZeneca)…
Current Challenges in Patient Centricity
ACT: What do you think are currently industry’s greatest challenges in patient centricity? Keunen: Patient centricity—that’s a big topic, indeed.…